SCHOTT starts production at new glass tubing plant in China, adding 20,000 tons of capacity for pharma
December 17, 2020, Jinyun, China
- Specialty glass manufacturer SCHOTT has commenced production at its new pharmaceutical tubing factory in China.
- The new plant will produce high-quality FIOLAX® borosilicate glass tubing – the base material for pharmaceutical packaging such as vials, ampoules, syringes and cartridges, which the vast majority of COVID-19 vaccine projects rely upon.
- SCHOTT has invested 60 million Euros in the new plant as part of a 1 billion USD investment in its global pharmaceutical business.
SCHOTT sells the glass to third-party packaging manufacturers, but also converts the tubes to vials and other pharmaceutical containers in-house. Pharmaceutical vials made by SCHOTT are used in 75% of COVID-19 vaccine projects around the world.
About SCHOTTSCHOTT is a leading international technology group in the areas of specialty glass, glass-ceramics and related high-tech materials. With over 130 years of experience, the company is an innovative partner to many industries, including the home appliance, pharma, electronics, optics, life sciences, automotive and aviation industries. SCHOTT has a global presence with production sites and sales offices in 34 countries. In the 2018/2019 fiscal year, the group generated sales of EUR 2.2 billion (US$ 2.54 billion) with over 16,200 employees. SCHOTT AG has its headquarters in Mainz (Germany) and is solely owned by the Carl Zeiss Foundation. This is one of the oldest private and largest science-promoting foundations in Germany. As a foundation company, SCHOTT assumes special responsibility for its employees, society and the environment.
Head of Corporate Communications